Ucla Medical Device Partnering Conference
Total Page:16
File Type:pdf, Size:1020Kb
INDUSTRY INVENTORS INVESTORS 3RD ANNUAL UCLA MEDICAL DEVICE PARTNERING CONFERENCE TUESDAY MARCH 10, 2015 CNSIUCLA CAMPUS Conference Program 9:15 am REGISTRATION/NETWORKING 10:00 am WELCOME—Emily Waldron Loughran 10:15 am INVESTORS PANEL Medical Device Startup Funding RCT Ventures | Johnson & Johnson Innovation | Life Science Angels | Seroba Kernel Life Sciences |Enterprise Ireland | The Brenner Group 11:30 am TRENDS IN HOSPITAL PURCHASING OF MEDICAL DEVICES UCLA Health | Kaiser Permanente 12:15 pm LUNCH 1:15 pm STARTUP COMPANY PITCHES Bone-Rad Therapeutics | Bruin Biometrics | Fluid Synchrony | QT Medical 2:15 pm NETWORKING OPPORTUNITIES 2:45 pm STARTUP COMPANY PITCHES CaliCast | Cayuga Biotech | GI Logic | Platinum Group Coatings 3:45 pm NETWORKING/EVENT CLOSE B UCLA Medical Device Partnering Conference © 2015 Regents of the University of California Contents Speaker Profiles 2 Startup Company Profiles 7 UCLA Available Medical Device Technologies 11 Cardiovascular Devices 12 CNS Technologies 14 Device Materials 15 Diagnostic Tools 16 Orthopedic Devices 19 Radiation Therapy & Oncology 19 Sensors & Patient Monitoring Devices 20 Surgical Tools 22 Conference Sponsors and Partner Organizations 25 Contact Information 26 Richard M. Brenner Andy DelGesso President & C.E.O. Executive Director and Medical Portfolio Manager The Brenner Group, Inc. Kaiser Permanente Rich Brenner founded The Brenner Group, Andy DelGesso is an Executive Director and Medical Inc.® (www.thebrennergroup.com) in 1987. The Portfolio Manager in Procurement & Supply at Brenner Group is a financial services firm providing Kaiser Permanente. In addition to managing $1.5B outsourced financial executives, financial advisory in purchases of medical products, equipment services and shareholder representative services and and services, he is active in Business Strategy serves as CEO. Development, Digital Health Integration, Supplier Relationship Management, and Outsourced Services He has also been an active angel investor in and Management. around Silicon Valley for many years. Andy has 20 years of experience in Strategic Sourcing One of these investments is Bridge Capital Holdings, and Supply Chain functions, both in the U.S. and the parent company of Bridge Bank, where Rich is abroad. His background includes work in many a founder, Director Emeritus, former member of the industries, including healthcare, IT, automotive, Board of Directors and former Chairman of the Audit agriculture, & manufacturing. Committee. Recently, he has focused his Angel Investing in the life sciences sector. Andy holds a bachelor’s degree in Business from Villanova University and is fluent in Japanese. He has worked in general and financial management, and has assisted many emerging companies in the roles of President, General Manager, Vice President and Chief Financial Officer. He has held executive level positions at Formaster Corporation, Corvus Systems Inc., US Leasing International Inc., ITEL Corporation, National BankAmericard (now VISA) and Autographic Business Forms Inc. He also served as venture capital consultant to Hillman Ventures. Rich is, or has served, as a board member at Affymax, Inc., e-Nicotine, Inc., Sandstone Diagnostics, Inc., PartMiner, Inc. Vida Systems, Inc., Vello Systems, Inc., Abound Logic, Inc., Pavad Medical Systems, Inc. Cardiovention, Inc., Chadmoore Wireless Group and QuickHealth. 2 UCLA Medical Device Partnering Conference Norm Gitis, PhD Paul M. Grand Managing Partner, Lymo Ventures Managing Director Screening Committee Chair, Life Science Angels RCT Ventures Norm Gitis obtained his PhD in Engineering from Paul M. Grand is a Managing Director for RCT the USSR Academy of Sciences in Moscow. Upon Ventures. At RCT, he is responsible for sourcing immigration to the US, he was a visiting professor at RCT’s investments in medical devices and MIT until IBM moved him to San Jose. He worked in representing RCT on the boards of its portfolio the disk drive industry, at IBM and then Maxtor. companies. Grand serves as Producer and Master of Ceremonies for the annual MedTech Idol Norm founded and ran two high-tech companies, competition that seeks to identify outstanding early- Center for Tribology, Inc. in Mountain View (1994– stage MedTech opportunities. 2000) and CETR in Campbell (2000–2011). He was twice named by the Business Journal the CEO of Grand has extensive experience in new company Top 20 Fastest Growing Private Companies in formation and operations. Prior to joining RCT, Northern California. Grand founded and operated eight high technology, medical device, and biotechnology companies. In Norm has authored over 150 scientific papers, three the life sciences, Grand was co-founder and VP of books and over two dozen patents, chaired and Operations of Imagine Pharmaceuticals, and co- organized over three dozen international scientific founder and CEO of MicroSurgeon in Los Angeles. conferences. Grand is actively involved in programs to Over the past three years, Norm has been pursuing encourage bio-entrepreneurship, innovation, and his passion of helping technology-based start-ups commercialization of University technologies. He with funding, IP and business development. Norm is on the Oversight Committees for the Coulter chairs a screening committee of Life Science Angels Translational Research Partnership Programs at USC and serves on a screening committee of the Band and University of Washington. Grand is a reviewer of Angels. for proof of concept and commercialization-focused funding programs for the University of California system, USC, University of Utah, and University of Colorado. UCLA Medical Device Partnering Conference 3 Thomas Lipkin, PhD Emily Waldron Loughran Head of New Ventures Director of Licensing UCLA OIP-ISR UCLA OIP-ISR Thomas Lipkin joined UCLA’s OIP-ISR in 2012 Emily Loughran joined UCLA’s OIP-ISR in 1994 as a and serves as Head of New Ventures. Dr. Lipkin technology transfer officer. Currently, as the Director and his team work to further the entrepreneurial of Licensing, she manages the licensing and patent environment at UCLA by building startup companies prosecution groups, and oversees the office’s large around UCLA’s intellectual property, serving as a portfolio of invention disclosures, patents, and resource to faculty members, aiding existing UCLA license agreements. Emily started in intellectual startups in sourcing financing and talent, and property administration at the City of Hope Medical helping secure additional funding for campus-wide Center where she was the Technology Transfer startup initiatives. Dr. Lipkin is also responsible Manager responsible for patenting and licensing for actively promoting UCLA’s intellectual property activities. Emily holds an MBA from USC and a BS assets and engaging with parties interested in from UC Berkeley. further developing early-stage technologies in the life sciences, physical sciences, and internet technology space. Previously, Dr. Lipkin was with Osage University Partners, a venture capital fund that invests exclusively in university-based startup companies. Dr. Lipkin received his B.S. in Biology from Indiana University and his Ph.D. in Cell Biology and Pathology from Columbia University. 4 UCLA Medical Device Partnering Conference Jennifer McKeever, MSc, BSc Brian O’Neill, PhD, MBA Senior Investment Analyst Manager, High Potential Start-Ups, Industrial & Seroba Kernel Life Sciences Lifesciences, High Growth Scaling Unit Enterprise Ireland Jennifer McKeever joined the team of Seroba Kernel Brian O’Neill is the Head of Industrial & Lifesciences in 2011. She graduated from University College, High Potential Start-Ups for Enterprise Ireland— Dublin with an honours degree in Pharmacology the Government of Ireland’s Trade and Technology in 2010. Jennifer then entered a Master’s degree Agency responsible for the internationalisation of programme in Biotechnology and Business to further indigenous Irish industry. Brian has spent over her interest in the interface of biomedical science with 20 years working with the lifesciences sector in commercialisation. Having placed first in her Master’s Ireland and internationally in a variety of private degree in 2011, Jennifer then joined Seroba Kernel’s sector/government roles ranging from basic Investment Team as an Investment Analyst. Jennifer is to applied research through to entrepreneur, a member of the Sandbox network, a global community technology transfer specialist, lifesciences business for ‘exceptional innovators’ and she guest-lectures on development adviser and Head of the indigenous venture capital at University College Dublin, Trinity Irish sector. College Dublin and the Royal College of Surgeons, In his current role Brian and his team are Ireland. Jennifer was promoted to Senior Analyst in responsible for the development and implementation 2014. of the strategic plan required to drive the continued Seroba Kernel is a European life sciences venture growth of Ireland’s vibrant start up community capital firm, focused on investing in breakthrough together with accelerating the global expansion of healthcare technologies that promise to improve lives Ireland’s most successful businesses. In addition, and make a difference worldwide. Headquartered he plays a key role in shaping the Irish ecosystem to in Ireland, we work with some of Europe’s best ensure its long-term development and evolution. entrepreneurs developing innovative medical devices, Brian had a PhD in Human Molecular Genetics diagnostics and therapeutic drugs. from Trinity